How Chiesi partners with early-stage science, and how to get on their radar
Reserve your seat
On 20 May, Open Innovation leads from Chiesi will share how a top-pharma company scouts, evaluates and partners on early-stage research, walking us through the different ways work can be considered for partnering.
Rare disease leads from Chiesi will also present their latest call (seeking in utero therapeutic approaches for rare diseases), which launched ahead of the session, creating a forum for discussion with interested prospective partners.
The team at Chiesi will show you what a good submission looks like, how opportunities move from first contact through to signed agreement, and where you can plug into their partnering ecosystem: submitting to their always-on open call, responding to active search campaigns, or joining their close network of contacts through Inpart.
Panelists
What we'll cover:
- How Chiesi’s The Impulse Open Innovation program operates, from scouting, triage and evaluation, through to agreement and execution
- Where Chiesi is looking across its Air, Care, and Rare portfolios, and what partnerable early-stage science looks like for each
- The different ways to engage with Chiesi - always-on open call, live campaigns, gallery membership, and direct partnering via The Impulse
- A closer look at their active call for opportunities - in utero therapeutic approaches for rare diseases
- Where Chiesi is using Inpart's Campaigns and Deal platforms to source and manage their partnering pipeline
- A Live Q&A with the Chiesi team
Who should attend:
- Technology Transfer Offices and Research Services teams from any therapeutic area overlapping Chiesi's interests
- Academic researchers working in respiratory, neonatal/specialty care, rare disease, and adjacent fields
- Biotech Founders, CEOs, and Heads of BD - especially those with early-stage assets
- Pharma R&D, BD, and External Innovation teams benchmarking best practices
- VCs active in early-stage biopharma partnering, particularly in Chiesi's therapeutic areas
About The Impulse by Chiesi
The Impulse by Chiesi is the company’s Open Innovation platform, , dedicated to scouting and piloting external solutions that advance patient care. Through calls for opportunities and partnership programs, The Impulse connects innovators with Chiesi expertise and a global network to accelerate impactful, sustainable healthcare innovations.. The team works with academic institutions, start-ups, biotechs and ecosystem partners across Europe, North America and beyond, with active collaborations including Karolinska Institutet, EIT Health, TechTour, and NOME.
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
In 2025, Chiesi invested 24.4% of its revenue in R&D. Headquartered in Parma, the company’s research and development centre works alongside six additional R&D hubs located in France, the United States, Canada, China, the United Kingdom, and Sweden.
For further information, please visit: https://www.chiesi.com/en
About Inpart
Inpart is the trusted platform for scientific partnering across the entire collaboration lifecycle, from discovery to alliance.
Our partnering ecosystem is home to 20,000+ scientific decision-makers from across industry and academia, connecting based on their research priorities and interests.
Our partnering data management platform streamlines the collaboration and alliance management phases of scientific partnerships.